Azzalure’s New 72-Hour Storage Rule: How UK Botulinum Toxins Compare

For aesthetic practitioners, Azzalure storage and refrigeration have traditionally gone hand in hand.

That has not ended—but the current approved UK product information has changed.

An unopened vial of Azzalure may now undergo a single exposure to temperatures up to 25°C for up to 72 hours. It can then be returned to refrigerated storage at 2°C–8°C for the remainder of its shelf life.

That is a meaningful improvement in temperature-excursion resilience. It may help clinics manage genuine delivery delays, fridge failures, power interruptions and other documented temperature excursions without automatically assuming affected stock must be discarded.

But the Azzalure storage change raises a wider question: are practitioners comparing botulinum toxin products properly—or simply using whichever brand their supplier promotes most heavily?

The UK market contains products with materially different storage requirements, presentations, preparation requirements, licensed indications and economics. Practitioners can browse Longeva Pharma’s Botulinum Toxins & Diluents range for current products and presentations available to eligible UK professionals.

There is no universal “best toxin”. There is the appropriately licensed product whose characteristics best fit the practitioner, patient, prescribing framework, storage controls, workflow and genuine treatment economics.

Does Azzalure Still Need to Be Refrigerated?

Yes. Azzalure has not become a room-temperature medicine. Its normal unopened storage condition remains refrigerated at 2°C–8°C and it must not be frozen.

The change concerns a defined temperature excursion. An unopened vial can undergo one exposure to temperatures up to 25°C for up to 72 hours. Following that qualifying exposure, it may be returned to refrigerated storage at 2°C–8°C for the remainder of its shelf life.

Eligible practitioners can view Azzalure 125 Units Single Vial, Azzalure 125 Units Dual, or explore the wider Galderma range.

Azzalure vs Other UK Botulinum Toxins: Storage Comparison

Botulinum toxin medicines should not be treated as interchangeable. Their potency units are product-specific, their licensed indications differ, and the approved preparation and storage requirements for the individual medicine must be followed.

This is an operational comparison, not a claim that one product is more effective or clinically superior. Practitioners should always consult the current approved product information. Browse the complete Botulinum Toxins & Diluents range.

Azzalure: Improved Temperature-Excursion Resilience

Azzalure remains a refrigerated medicine. Its important new characteristic is the defined treatment of one qualifying excursion: the vial must remain unopened; temperature must not exceed 25°C; exposure must not exceed 72 hours; the allowance is for a single exposure; and the qualifying vial may subsequently return to 2°C–8°C for the remainder of its shelf life.

Azzalure remains a powder requiring reconstitution. Its Speywood units are specific to the product and must not be casually converted into units used by other preparations.

Explore Azzalure and the Galderma toxin range

View Azzalure 125 Units Single Vial, Azzalure 125 Units Dual, or browse Galderma.

Letybo: Attractive Economics, Stricter Refrigeration

Letybo may be commercially attractive to clinics and suppliers. A lower acquisition price can potentially improve clinic margin or support competitive treatment pricing, but it is not the only consideration.

The current UK SmPC requires Letybo to be stored and transported refrigerated at 2°C–8°C. It does not state an equivalent allowance permitting an unopened vial to spend up to 72 hours at 25°C and subsequently return to refrigeration.

Clinics should consider whether delivery arrangements, fridge monitoring, contingency planning and stock controls reliably support its approved storage requirements, alongside its specific licensed indication.

Explore Letybo

View Letybo 50IU or visit the Letybo collection.

Alluzience: Ready to Use, With a Shorter Room-Temperature Window

Alluzience is supplied as a ready-to-use solution. Removing reconstitution may save preparation time and removes one preparation step from clinic workflow. But ready to use does not mean free from temperature control.

Alluzience should normally be refrigerated at 2°C–8°C, protected from light and not frozen. Its current UK product information provides a defined unopened period at temperatures up to 25°C, but this is materially shorter than Azzalure’s new 72-hour provision.

Explore Alluzience

View Alluzience 125 Units Single Vial or browse Galderma.

Relfydess: Ready to Use With Defined Room-Temperature Stability

Relfydess is supplied as a ready-to-use solution. Its normal storage condition remains refrigerated at 2°C–8°C, and its current UK product information provides defined stability information for an unopened vial at 25°C.

Preparation, storage, licensed indication, stock turnover, staff familiarity and overall treatment economics can all matter. Relfydess potency units are product-specific and are not interchangeable with units belonging to another preparation.

Explore Relfydess

View Relfydess 100 Units/ml or compare it through Galderma.

Nuceiva: Another Refrigerated Toxin With Its Own Profile

Nuceiva is supplied as a powder for solution for injection and requires reconstitution. Its current UK product information requires unopened Nuceiva to be stored refrigerated at 2°C–8°C and does not state an equivalent Azzalure-style unopened room-temperature provision.

Practitioners should compare licensed indications rather than treating every product simply as “a toxin”. The authorised indication, patient criteria, dosing, preparation and administration requirements should always be checked against the current SmPC.

Explore Nuceiva

View Nuceiva 50 Units and compare it with the wider Botulinum Toxins & Diluents range.

BOCOUTURE: Substantial Unopened-Storage Flexibility

BOCOUTURE is operationally distinctive. The current UK SmPC states that unopened BOCOUTURE should not be stored above 25°C. Routine refrigeration is therefore not required for unopened BOCOUTURE under its approved storage conditions.

Storage convenience does not remove requirements for appropriate prescribing, preparation, patient assessment, administration, traceability and product-specific competence.

Explore BOCOUTURE and Merz Aesthetics

View BOCOUTURE 50 & 100 Units, visit the BOCOUTURE collection, or explore Merz Aesthetics.

BOTOX: Familiarity, Broader Licensed Uses and Temperature-Controlled Storage

BOTOX has extensive professional recognition and a range of licensed medical and aesthetic uses. The current UK SmPC requires unopened BOTOX to be stored either refrigerated at 2°C–8°C or frozen at −5°C to −20°C.

Its familiarity and breadth should be assessed alongside storage requirements, presentation, acquisition cost and intended licensed use. Brand recognition alone is not a clinical selection policy.

Explore BOTOX

Browse the BOTOX collection, including BOTOX 50 Allergan Units and BOTOX 100 Allergan Units, or compare the wider Botulinum Toxins & Diluents category.

What Happens if an Azzalure Delivery Gets Warm?

A temperature excursion should not be dealt with by guesswork. Establish whether the vial was unopened, the maximum temperature, excursion duration, whether a qualifying excursion occurred previously, whether temperature remained at or below 25°C, whether exposure remained within 72 hours, and whether adequate evidence supports the temperature history.

Where circumstances cannot reliably be established, seek appropriate pharmaceutical or manufacturer advice. The new rule provides additional resilience; it does not remove the need for cold-chain governance.

What Happens After a Clinic Fridge Failure?

A refrigerator alarm, power failure or temperature logger showing an excursion should trigger a documented assessment. Establish duration and maximum temperature, identify affected medicines and assess each product against its own approved storage requirements.

A refrigerator containing several toxin brands cannot necessarily be assessed using one universal excursion rule. Different medicines have different approved storage requirements.

Botulinum Toxin Units Are Not Interchangeable

The unit systems used for botulinum toxin preparations are product-specific. A numerical unit comparison across different brands does not establish clinical equivalence. Simplistic “price per unit” comparisons can therefore be misleading.

Practitioners moving between preparations require product-specific knowledge, appropriate prescribing and administration protocols, and an understanding of the relevant authorised product information. Compare the current professional range through Botulinum Toxins & Diluents.

The Cheapest Toxin Vial Is Not Always the Cheapest Treatment

Headline acquisition price is only one component of treatment economics. Real cost can also be influenced by product-specific dosing, suitable treatments obtained from a presentation, wastage, reconstitution, preparation time, delivery, refrigeration and monitoring, failed deliveries or excursions, staff familiarity, prescribing arrangements, stock turnover and licensed indications.

Good procurement looks beyond the invoice price.

Do Not Allow a Supplier to Choose Your Toxin for You

Pharmacies, wholesalers and other suppliers are commercial organisations. Different products can have different acquisition costs, stock commitments, commercial arrangements and margins. There is nothing inherently wrong with a supplier explaining a product it stocks. The problem arises if commercial preference is presented as neutral clinical advice.

A responsible supplier should help practitioners understand their options rather than reduce a complex product decision to a single brand. The final selection should remain an informed clinical and business decision within the practitioner’s competence and prescribing framework.

Build Your Toxin Range Around Your Clinic—not Your Supplier

A clinic does not necessarily need every botulinum toxin available. It does need a defensible reason for the products it chooses.

The better question is: “Which appropriately licensed product best fits my patients, competence, prescribing arrangements, storage controls, workflow and genuine treatment economics?”

Practitioners can compare current options through Longeva Pharma’s Botulinum Toxins & Diluents collection.

The Bottom Line: Azzalure Storage Has Changed, but Product Choice Is Bigger Than Storage

Azzalure’s new 72-hour storage allowance is a meaningful development. Its normal storage condition remains 2°C–8°C, but an unopened vial may now undergo one qualifying exposure to temperatures up to 25°C for up to 72 hours before returning to refrigeration for the remainder of its shelf life.

That does not make Azzalure universally better. Letybo may present attractive acquisition economics. Alluzience removes reconstitution and provides its own defined room-temperature provision. Relfydess is ready to use with defined unopened-vial room-temperature stability. Nuceiva provides another refrigerated, reconstituted option. BOCOUTURE provides substantial unopened-storage flexibility. BOTOX combines extensive familiarity and broader licensed uses with temperature-controlled unopened storage.

These medicines are different. Their potency units are product-specific and non-interchangeable. Their licensed indications, presentations, preparation requirements, storage requirements, acquisition prices and genuine treatment economics can differ.

Choose the product deliberately. Understand why you chose it. Follow its individual SmPC. Do not outsource that decision to whoever happens to be selling the vial.

Compare Botulinum Toxins Through Longeva Pharma

Eligible UK practitioners can explore the complete Botulinum Toxins & Diluents range or go directly to Galderma, Letybo, BOCOUTURE, Merz Aesthetics and BOTOX.

Prescription-only medicines are supplied only through the appropriate professional, prescription and pharmacy route. Product availability, professional eligibility and applicable pharmacy requirements should be checked on the individual product page.

This article is intended for UK healthcare professionals and aesthetic practitioners. It provides a high-level comparison of current UK product information and does not replace the individual Summary of Product Characteristics, clinical judgement, prescribing requirements or appropriate medicines-governance procedures. Product information can change; practitioners should consult the current approved SmPC before prescribing, supplying, storing or administering any medicine.